Company / R&D Expense
Apogee Therapeutics, Inc. R&D Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$167.9M
FY2024
5-year range
$27.8M / $167.9M
FY2022-FY2024
Trend
+145.3%
vs FY2023
Sector context
#97 of 210
Health Care
What the data says
At $168M, Apogee Therapeutics, Inc.'s r&d expense ranks #97 of 210 in the Health Care sector. Improved from $28M to $168M over the past 2 years.
Based on SEC 10-K filings.
$168M in FY2024.
Improved from $28M to $168M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#97 of 210 in Health CareTop 46% of 210This company $167.9M Sector average $644.1M
▼
-73.9% below sector average
Key checks
Key Insights
- In FY2024, r&d expense increased 145.3% year-over-year.
- Ranks #97 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $167.9M | +145.3% |
| FY2023 | $68.4M | +146.3% |
| FY2022 | $27.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026